DGCI

DGCI sends Notice to Glenmark Pharmaceuticals over antiviral drug FabiFlu for COVID-19 Patients

DGCI sends Notice to Glenmark Pharmaceuticals over antiviral drug FabiFlu for COVID-19 Patients

Glenmark Pharmaceuticals has received a notice from the Drugs Controller General of India (DGCI) regarding pricing of antiviral drug FabiFlu that has been effective is recovery of some COVID-19 pat